Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc. announced EC's approval of INAQOVI® for treating newly diagnosed acute myeloid leukaemia in adults unfit for standard induction chemotherapy.

Atamyo Therapeutics made public its submission of a CTA for ATA-200 in European territories.

BeiGene, Ltd. revealed that TEVIMBRA®(tislelizumab) has received approval by the EC to be used as a single therapy for addressing unresectable.

ESSA Pharma Begins Phase 2 trial of Masofaniten (EPI-7386) in Combination with Enzalutamide for Patients Suffering from Metastatic Castration-Resistant Prostate Cancer.

FDA Prioritizes Review of Merck's Additional New Drug Submission for WELIREG® (belzutifan) for Previously Treated Patients with Advanced Renal Cell Carcinoma.

Pfizer Inc. confirmed the received marketing approval by the EC for LITFULO™ (ritlecitinib)  aimed for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above.

Heidelberg Pharma AG announced it began patient recruitment for the fifth group in the Phase I/IIa trial of their main development candidate, HDP-101, with a dose of 100 µg/kg.

Orexo AB recently submitted its NDA to the US FDA for OX124, a high-dose, nasally-administered treatment for opioid overdoses.

Kite's Car T-cell Therapy Yescarta® exhibits a substantial treatment response rate and durable remission for patients with relapsed/resistant Large B-cell Lymphoma.

Vividion Therapeutics, Inc., confirmed the commencement of patient dosing for a Phase I cancer clinical trial concerning its experimental oral agent, KEAP1 activator VVD-130037.

NeuroBo Pharmaceuticals, Inc. has started its Phase 2a clinical trial using DA-1241, a unique GPR119 agonist, to treat the first patient with nonalcoholic steatohepatitis.

GSK plc has confirmed that Ojjaara(momelotinib), a daily oral JAK1/JAK2 and activin A receptor type 1 inhibitor, has received approval from the US FDA.